CytoDyn Secures Anonymous Funding for Expanded Access Program in Triple-Negative Breast Cancer
Event summary
- CytoDyn Inc. received anonymous funding to launch an Expanded Access Program (EAP) for leronlimab in triple-negative breast cancer (TNBC).
- The EAP, administered by WEP Clinical, is expected to open for patient referrals in March 2026, pending FDA approval.
- The program aims to provide compassionate access to leronlimab for patients who have exhausted standard treatment options.
- The EAP will also serve as an observational avenue to study PD-L1 induction following leronlimab treatment.
The big picture
CytoDyn's EAP for leronlimab in TNBC reflects a strategic shift towards broadening patient access while generating real-world data to support future regulatory pathways. This move aligns with broader industry trends of leveraging expanded access programs to accelerate the development of promising cancer therapies, particularly for aggressive and treatment-resistant indications like TNBC. The anonymous funding underscores the growing interest in leronlimab's potential, but the success of the program will hinge on FDA approval and the clinical outcomes observed.
What we're watching
- Regulatory Approval
- Whether the FDA will approve CytoDyn's revised protocol submission for the EAP by March 2026.
- Clinical Efficacy
- How the observational data from the EAP will impact the understanding of leronlimab's mechanism of action in TNBC.
- Funding Dynamics
- The potential for additional anonymous or institutional funding to support further clinical trials or expanded access programs.
Related topics